{"id":103364,"date":"2025-07-29T23:56:10","date_gmt":"2025-07-29T23:56:10","guid":{"rendered":"https:\/\/www.europesays.com\/us\/103364\/"},"modified":"2025-07-29T23:56:10","modified_gmt":"2025-07-29T23:56:10","slug":"how-will-trumps-e-u-tariffs-affect-drug-prices-nbc-los-angeles","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/us\/103364\/","title":{"rendered":"How will Trump\u2019s E.U. tariffs affect drug prices? \u2013 NBC Los Angeles"},"content":{"rendered":"<p>President Donald Trump\u2019s <a href=\"https:\/\/www.nbcnews.com\/business\/business-news\/us-european-union-trade-deal-tariff-rate-fifteen-percent-rcna218380\" rel=\"nofollow noopener\" target=\"_blank\">trade deal with the European Union<\/a> may lead to higher prices for brand-name drugs in the United States, including blockbuster medications like Ozempic and Wegovy, experts say.<\/p>\n<p>The trade deal, announced Sunday, places a 15% tariff on most imported goods from the E.U., including pharmaceuticals. While that comes in well below <a href=\"https:\/\/www.cnbc.com\/2025\/07\/08\/trump-threatens-pharmaceutical-tariffs-200.html\" rel=\"nofollow noopener\" target=\"_blank\">the 200% tariffs Trump had threatened<\/a> on pharmaceutical imports earlier this month, it\u2019ll still have an impact.<\/p>\n<p>Pharmaceuticals are the United States\u2019 fifth largest import, said Dr. Aaron Kesselheim, a professor of medicine at Harvard Medical School. <\/p>\n<p>Europe is a major manufacturing hub for brand-name drugs in particular. <a href=\"https:\/\/qualitymatters.usp.org\/over-half-active-pharmaceutical-ingredients-api-prescription-medicines-us-come-india-and-european\" rel=\"nofollow noopener\" target=\"_blank\">Nearly half of the active ingredients<\/a> for brand-name drugs taken in the U.S. are produced in European countries such as Ireland, Germany, Italy and Belgium, Kesselheim said. Europe is also where many drugmakers do final steps, such as filling and packaging.<\/p>\n<p>Novo Nordisk\u2019s diabetes and obesity drugs Ozempic and Wegovy are both produced in Denmark. Botox, made by Allergen, and the cancer drug Keytruda from drugmaker Merck are made in Ireland. (In recent years, however, more of Keytruda\u2019s manufacturing has shifted to the U.S.) <\/p>\n<p>While brand-name drugs only account for about 10% of prescriptions filled in the U.S., they make up about 80% of all drug spending, Kesselheim said.<\/p>\n<p>\u201cThat\u2019s because they\u2019re priced so high,\u201d he said. \u201cEach individual [generic] statin is pennies, whereas Botox is thousands to tens of thousands of dollars.\u201d<\/p>\n<p>In the short term, drug companies might increase the list prices of these products to account for the higher cost, said Rena Conti, an associate professor at Boston University\u2019s Questrom School of Business.<\/p>\n<p>\u201cU.S. consumers will pay more at the pharmacy counter for these drugs,\u201d Conti said. \u201cWhat patients pay at the pharmacy counter reflects drug companies\u2019 set price list.\u201d<\/p>\n<p>Kesselheim said it\u2019s an open question whether patients would even notice the higher prices, given that brand-name drugs are already so expensive. <\/p>\n<p>\u201cThe drug prices are already two to three times higher in the United States than they are in other countries,\u201d he said. \u201cThere is a lot more room for drug companies [to charge more.]\u201d<\/p>\n<p>\n\t\t\t\t\t\t\t\tTariffs or customs duties are a tax on products purchased from abroad, and they are used by practically all countries\n\t\t\t\t\t\t\t<\/p>\n<p><a href=\"https:\/\/www.nbcnews.com\/health\/health-news\/trumps-tariffs-raise-cost-generic-drugs-us-rcna181221\" target=\"_blank\" rel=\"noopener nofollow\">Generic drugs<\/a>, on the other hand, are often sold at close to the cost that they\u2019re made. About 9 out of 10 prescription drugs taken in the U.S. are generics, Kesselheim added. <\/p>\n<p>The Pharmaceutical Research and Manufacturers of America, a drug industry trade group, did not immediately respond to a request for comment.<\/p>\n<p>The E.U. tariffs aren\u2019t expected to affect the prices of many generic drugs.<\/p>\n<p>Some generic drugs are made in Europe, but the majority are manufactured in countries like China and India, said Arthur Caplan, the head of the division of medical ethics at NYU Langone Medical Center in New York City.<\/p>\n<p>There have been concerns that tariffs on these countries could \u200bdrive up the cost of generic drugs and <a href=\"https:\/\/www.nbcnews.com\/health\/health-news\/trumps-china-tariffs-are-likely-drive-drug-prices-spur-shortages-rcna190426\" rel=\"nofollow noopener\" target=\"_blank\">exacerbate drug shortages<\/a>. Generic drugs aren\u2019t a lucrative enough business for companies to invest in new manufacturing facilities in the U.S., Caplan said. <\/p>\n<p>A spokesperson for the Association for Accessible Medicines, a trade group that represents generic drugmakers, said the group is still assessing the potential impact of the tariffs as well as the specifics of the trade deal.<\/p>\n","protected":false},"excerpt":{"rendered":"President Donald Trump\u2019s trade deal with the European Union may lead to higher prices for brand-name drugs in&hellip;\n","protected":false},"author":3,"featured_media":103365,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5123],"tags":[1582,276,2961,224,5337,4352],"class_list":{"0":"post-103364","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-los-angeles","8":"tag-ca","9":"tag-california","10":"tag-la","11":"tag-los-angeles","12":"tag-losangeles","13":"tag-trump-administration"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@us\/114939231220525574","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/103364","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/comments?post=103364"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/103364\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media\/103365"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media?parent=103364"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/categories?post=103364"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/tags?post=103364"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}